Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 84 clinical trials
Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent Platinum-resistant Ovarian Cancer.

Multicenter Phase II study on Decitabine-Carboplatin combination in platinum resistant ovarian cancer patients. Patients will receive study treatment until disease progression is

  • 2 views
  • 19 Jun, 2021
  • 1 location
Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia

This is a phase 2, single-center, single-arm, open-label trial. Simon's two-stage design is performed to evaluate the efficacy of low-dose Decitabine in refractory aplastic anemia.

  • 0 views
  • 21 May, 2021
  • 1 location
Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma

To evaluate the efficacy and safety of CD19 PD-1/CD28-CAR-T sequential low-dose decitabine in the treatment of relapse or refractory B cell lymphoma.

  • 0 views
  • 20 Jun, 2021
  • 1 location
Study of ASTX727 vs IV Decitabine in MDS CMML and AML

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727

blast cells
astx727
direct bilirubin
decitabine
induction chemotherapy
  • 269 views
  • 27 Jan, 2021
  • 93 locations
An Open-Label Multicenter Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with low-dose cytarabine (LDAC) or Decitabine for the treatment of adults with Acute Myeloid Leukemia (AML

cytarabine
decitabine
cancer
refractory acute myeloid leukemia (aml)
  • 2 views
  • 27 Jan, 2021
  • 27 locations
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations

Decitabine. Patients who achieve complete remission (CR) and who are MRD negative by flow cytometry after course one of DA will receive one further course of DA, with a randomisation to receive, either a

blast cells
daunorubicin
vosaroxin
cladribine
myeloid leukemia
  • 381 views
  • 23 Jan, 2021
  • 83 locations
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided …

bilateral oophorectomy
cancer
vasectomy
anemia
  • 0 views
  • 22 Jun, 2021
  • 158 locations
Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia

transplant failure. We reported previously that patients with relapse or refractory AL were at very high risk of relapse post allo-HSCT, with cumulative relapse rate of 50-80%. Decitabine has been

cyclophosphamide
busulfan
remission
acute leukemia
cell transplantation
  • 1 views
  • 23 Jan, 2021
  • 1 location
Ruxolitinib and Decitabine for High Risk Hematological Malignancies

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Decitabine intensified Conditioning Regimen in Patients with High Risk hematological malignancies undergoing

  • 0 views
  • 25 Jan, 2021
  • 1 location
Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC

To evaluate the effect of novel DNA demethylating agents in the treatment of metastatic TNBC

metastasis
HER2
immunostimulant
erbb2
cancer
  • 2 views
  • 24 Jan, 2021
  • 1 location